Tatmyctofusp: More Than a Molecule, A Platform

At its core, the platform delivers a time‑limited, MYC‑mediated activation program that improves metabolic fitness, resilience, and effector function of immune cells exposed to tumor‑driven suppression.

Platform capabilities

1. Broad immune‑cell applicability: The platform is designed to potentially support T cells, NK cells, and potentially other effector subsets; compatible with CAR‑T, TCR‑T, NK programs and general ex vivo conditioning.
2. Dual modality:
   • Standalone therapeutic (in vivo immune‑reconditioning)
   • Ancillary enhancer (optimizing adoptive cell therapies ex vivo or in vivo)
3. Self‑limited action: ~3–5‑day biological window enables reversible, non‑genetic conditioning.
4. Expansion beyond immune-oncology (preclinical): Signals promise in HSC engraftment and immune reconstitution, broadening applicability to transplant and regenerative settings.

Product portfolio

Krysaygio™ — ex vivo immune‑cell therapy for oncology indications
Tatmyctotrans‑E™ — ex vivo immune‑cell conditioning enhancer
Tatmyctotrans‑A™ — in vivo adjunct co‑administered with other immunotherapies
Treactivus™ — injectable (sub cutaneous) veterinary formulation